These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8236454)

  • 21. Inhibitors of protein farnesyltransferase as novel anticancer agents.
    Ohkanda J; Knowles DB; Blaskovich MA; Sebti SM; Hamilton AD
    Curr Top Med Chem; 2002 Mar; 2(3):303-23. PubMed ID: 11944822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Farnesyltransferase inhibitors: targeting the molecular basis of cancer.
    Oliff A
    Biochim Biophys Acta; 1999 May; 1423(3):C19-30. PubMed ID: 10382537
    [No Abstract]   [Full Text] [Related]  

  • 23. Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans.
    Hara M; Han M
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3333-7. PubMed ID: 7536929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel isoprenoid modified proteins in Halobacteria.
    Sagami H; Kikuchi A; Ogura K; Fushihara K; Nishino T
    Biochem Biophys Res Commun; 1994 Sep; 203(2):972-8. PubMed ID: 8093082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of coenzyme Q biosynthesis.
    Appelkvist EL; Aberg F; Guan Z; Parmryd I; Dallner G
    Mol Aspects Med; 1994; 15 Suppl():s37-46. PubMed ID: 7752843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells.
    Ren Z; Elson CE; Gould MN
    Biochem Pharmacol; 1997 Jul; 54(1):113-20. PubMed ID: 9296357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Farnesyl transferase inhibitors (anti-Ras). A new class of anticancer agents].
    Levy R
    Presse Med; 1995 Apr 15-22; 24(15):725-9. PubMed ID: 7784406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of mono- and bisubstrate inhibitors of protein farnesyltransferase and inducers of apoptosis from a pepticinnamin E library.
    Thutewohl M; Kissau L; Popkirova B; Karaguni IM; Nowak T; Bate M; Kuhlmann J; Müller O; Waldmann H
    Bioorg Med Chem; 2003 Jun; 11(12):2617-26. PubMed ID: 12757727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [CAAX peptidomimetics: their farnesyltransferase inhibition activity and antitumor effect].
    Ohkanda J
    Seikagaku; 2002 Jan; 74(1):46-50. PubMed ID: 11889772
    [No Abstract]   [Full Text] [Related]  

  • 34. Mode of action of farnesyltransferase inhibitors.
    Prendergast GC
    Lancet Oncol; 2000 Oct; 1():73. PubMed ID: 11905670
    [No Abstract]   [Full Text] [Related]  

  • 35. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
    Prendergast GC; Oliff A
    Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and early structure-activity relationship of farnesyltransferase inhibitors which mimic both the peptidic and the prenylic substrate.
    Schlitzer M; Böhm M; Sattler I; Dahse HM
    Bioorg Med Chem; 2000 Aug; 8(8):1991-2006. PubMed ID: 11003144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
    Bell IM
    J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
    [No Abstract]   [Full Text] [Related]  

  • 38. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ras regulatory interactions: novel targets for anti-cancer intervention?
    Prendergast GC; Gibbs JB
    Bioessays; 1994 Mar; 16(3):187-91. PubMed ID: 8166672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological activity of semipeptoid farnesyltransferase inhibitors.
    Reuveni H; Gitler A; Poradosu E; Gilon C; Levitzki A
    Bioorg Med Chem; 1997 Jan; 5(1):85-92. PubMed ID: 9043660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.